XML 41 R25.htm IDEA: XBRL DOCUMENT v3.25.1

NET REVENUES

12 Months Ended

Dec. 31, 2024

NET REVENUES

NET REVENUES

NOTE 19 - NET REVENUES:

​

​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​
​	​	​	Year Ended December 31,
​		​	2024	​	2023	​	2022
​	​	​	U.S dollars in thousands
Licensing revenues (1)	​	​	547	​	—	​	2,000
Sales of products (2)	​	​	7,496	​	6,530	​	59,800
​			8,043		6,530	​	61,800

​

(1) Revenues related to the license agreement with Gaelan for Talicia® in the UAE, see note 15(7) above.

(2) In 2024 and 2023, the Company recognized contra-revenues of ($0.9) million and ($2.6) million, respectively, for Movantik®, primarily due to returns following its divestiture on February 1, 2023 (see note 15(6) above). In 2022, net revenues for Movantik® were $52.1 million. Correspondingly, in 2024, 2023 and 2022, net revenues from sales of other products (mainly Talicia®) were $8.4 million, $9.1 million, and $7.7 million, respectively.

X

- References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for revenue from contracts with customers.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2024-01-01
-Section Presentation
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2024-01-01
-Section Disclosure
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:textBlockItemType
Balance Type:	na
Period Type:	duration